RPT1G not checked

Remedy Plan, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“RPT1G is a selective hyperbolic NAMPT inhibitor. RPT1G is administered orally.”In the company’s words, NCT07107126 on ClinicalTrials.gov
Tested for
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Main trialPhase 1
“The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).”In the company’s words, NCT07107126 on ClinicalTrials.gov

Other drugs for Acute Myeloid Leukemia

All 140 drugs for Acute Myeloid Leukemia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 1 Dec 2028 Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Phase 1Completed 14 May 2025 A Study of RPT1G After Single and Multiple Doses in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RPT1G

Following is part of Solo: you see every change to RPT1G the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in